



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/001,934	11/15/2001	Zoltan Nagy	GPCG-P01-003	8886

28120 7590 09/25/2006

FISH & NEAVE IP GROUP
ROPES & GRAY LLP
ONE INTERNATIONAL PLACE
BOSTON, MA 02110-2624

EXAMINER

CANELLA, KAREN A

ART UNIT	PAPER NUMBER
----------	--------------

1643

DATE MAILED: 09/25/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/001,934

Applicant(s)

NAGY ET AL.

Examiner

Karen A. Canella

Art Unit

1643

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☐ Claim(s) See Continuation Sheet is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) 11, 18, 20, 22-24, 26, 28, 33-36, 55, 56, 61, 67, 71, 73, 121 and 123 is/are rejected.
- 7) ☐ Claim(s) See Continuation Sheet is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 1/28/04 7/3/06.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____.
- 5) ☐ Notice of Informal Patent Application
- 6) ☒ Other: See Continuation Sheet.

Continuation of Disposition of Claims: Claims pending in the application are 7-29,33-37,43,55,56,59-63,67,71-79,81-87,92-95,117,118 and 120-129.

Continuation of Disposition of Claims: Claims objected to are 7-10,12-17,19,21,25,27,29,37,43,59,60,62,63,72,74-77,79,81-87,92-95,117,118,120,122 and 124-129.

Continuation of Attachment(s) 6). Other: Raw Sequence Listing Error Report.

DETAILED ACTION

Claims 22, 23, 67 and 81 have been amended. Claims 7-29, 33-37, 43, 55, 56, 59-63, 67, 71-79, 81-87, 92-95, 117, 118 and 120-129 are pending and under consideration.

Text of Title 35, U.S. code not found in this action can be found in a prior action.

The specification is objected to for lack of compliance to the Sequence Rules. The CRF for the Sequence Listing submitted January 28, 2004 has not been entered due to the errors outlined on the attached Raw Sequence Error Report.

Appropriate correction is required.

Claims 7-29, 33-37, 43, 55, 56, 59-63, 67, 71-79, 81-87, 92-95, 117, 118, 120-129 are objected to because of the following informalities: The claims do not comply with the Sequence rules for the reasons set forth above.. Appropriate correction is required.

Claims 11, 18, 22-24, 26, 28, 33-36, 55, 56, 67, 71, 73, 121 and 123 are rejected under 35 U.S.C. 102(b) as being anticipated by Viken et al (Human Immunology, 1995, Vol. 43, pp. 200-206, reference of the IDS filed February 6, 2003).

Viken et al disclose the human IgM antibody, 5643, wherein said antibody is cytotoxic against the B-lymphoblastoid cell lines of BTB, BM9 and Madura (page 200, second column and page 201, Table 1) which fulfills the limitations of claims 73. Viken et al disclose that said antibody is specific to HLA-DR8 0801 (page 202, under the heading "Specificity of mAb 5643"). Viken et al disclose the use of the 5643 hybridoma supernatant in HLA typing of class II positive cells which fulfills the specific embodiment of claim 55 requiring a diagnostic composition. Viken et al disclose that the 5643 antibody does not bind the 0802 or 0804 subtypes of DR8 and that the only difference between these two subtypes is a ser to Asp substitution at residue 57 and a Phe to Ile substitution at residue 67 on the beta chain (page 202, under the heading "Specificity of mAb 5643"). Viken et al also disclose that another mAb, L243, which binds to the DR alpha chain inhibits binding of the 5643 antibody (page 205, second full paragraph). The 5643 antibody fulfills the specific embodiment of claim 33 because

Art Unit: 1643

a whole IgM antibody is a multivalent polypeptide including at least the F(ab')₂ portion of the antibody. The 5643 antibody fulfills the specific embodiments of claims 34, 35 and 56 because an IgM antibody includes disulphide bonds and the "J" chain, both of which can be construed as a cross-linking moiety (Roitt et al, Immunology (text), 1993, page 4.5, figure 4.9) which was confirmed prior to binding to the target cell.

Viken et al do not specifically disclose the epitope of the 5643 antibody, however, it would be reasonable to conclude that the epitope was not a linear epitope and comprised amino acid residues on both the alpha and the beta chains because binding of the 5643 antibody was influenced by amino acid substitutions to the beta chain, as well as competition from a known antibody which bound to the alpha chain. Viken et al do not specifically disclose the sequence of the antigen binding domains of the 5643 antibody, however, the claimed antibodies appear to be the same as the prior art antibodies in terms of human origin, target antigen and cytotoxicity to lymphoid cells, absent a showing of unobvious differences. The Office does not have the facilities and resources to provide the factual evidence needed in order to establish that the product of the prior art does not possess the same material, structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is on the applicant to prove that the claimed product is different from those taught by the prior art and to establish patentable differences. See *In re Best* 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and *Ex parte Gray* 10 USPQ 2d 1922 (PTO Bd. Pat. App. & Int. 1989).

Claims 11, 20, 22-24, 26, 28, 33-36, 55, 56, 61, 67, 73 and 78 are rejected under 35 U.S.C. 102(b) as being anticipated by Kolstad et al (Tissue Antigens, 1988, Vol. 31, pp. 90-97).

Kolstad et al disclose the cytotoxic human IgM antibody, TrH6, which binds specifically kills B cells expressing HLA-DR52W (page 91, under the heading of "Microcytotoxicity assays" and page 92, Table 1) which fulfills the limitation of claim 20 and claim 78. Kolstad et al disclose that the TrH6 antibody was iodine labeled (page 91 under the heading of "Purification and iodination of mAbs") which fulfills the specific embodiment of claim 61 requiring the detectable label. The TrH6 antibody fulfills the specific embodiments of claims 34, 35 and 56 because an IgM antibody includes disulphide bonds and the "J" chain, both of which can be

Art Unit: 1643

construed as a cross-linking moiety (Roitt et al, Immunology (text), 1993, page 4.5, figure 4.9) which was confirmed prior to binding to the target cell.

Kolstad et al do not specifically disclose the sequence of the antigen binding domains of the TrH6 antibody, or the however, the claimed antibodies appears to be the same as the prior art antibodies in terms of human origin, target antigen and cytotoxicity to lymphoid cells, absent a showing of unobvious differences. The Office does not have the facilities and resources to provide the factual evidence needed in order to establish that the product of the prior art does not possess the same material, structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is on the applicant to prove that the claimed product is different from those taught by the prior art and to establish patentable differences. See *In re Best* 562F.2d 1252, 195 USPQ 430 (CCPA 1977) and *Ex parte Gray* 10 USPQ 2d 1922 (PTO Bd. Pat. App. & Int. 1989).

All other rejections and objections as set forth in the previous Office action are withdrawn in light of applicants arguments.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen A. Canella whose telephone number is (571)272-0828. The examiner can normally be reached on 10-6:30 M-F.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571)272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.


Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/001,934
Art Unit: 1643

Page 5

Karen A. Canella, Ph.D.
9/17/2006


KARENA CANELLA PHD
PRIMARY EXAMINER



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/001,934B
Source: 1FW/6
Date Processed by STIC: 2/3/04

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 703-308-4212; FAX: 703-308-4221

Effective 12/13/03: TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkr41note.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/efb/efs/downloads/documents.htm>> , EFS Submission User Manual - cPAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
3. Hand Carry directly to (EFFECTIVE 12/01/03):
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 4B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 10/08/03



IFW16

RAW SEQUENCE LISTING

DATE: 02/03/2004

PATENT APPLICATION: US/10/001,934B

TIME: 11:42:46

Input Set : N:\DA\pto.da.txt

Output Set: N:\CRF4\01292004\J001934B.raw

4 <110> APPLICANT: NAGY et al.
 6 <120> TITLE OF INVENTION: HUMAN POLYPEPTIDES CAUSING OR LEADING TO THE KILLING
 7 OF CELLS INCLUDING LYMPHOID TUMOR CELLS
 9 <130> FILE REFERENCE: GPCG-P01-003
 11 <140> CURRENT APPLICATION NUMBER: 10/001934B
 12 <141> CURRENT FILING DATE: 2001-11-15
 14 <150> PRIOR APPLICATION NUMBER: PCT/US01/15625
 15 <151> PRIOR FILING DATE: 2001-05-14
 17 <150> PRIOR APPLICATION NUMBER: EP 00 11 0065.0
 18 <151> PRIOR FILING DATE: 2000-05-12
 20 <150> PRIOR APPLICATION NUMBER: US 60/238,762
 21 <151> PRIOR FILING DATE: 2000-10-06
 23 <160> NUMBER OF SEQ ID NOS: 62
 25 <170> SOFTWARE: PatentIn version 3.2
 28 <210> SEQ ID NO: 1
 29 <211> LENGTH: 10
 30 <212> TYPE: PRT
 31 <213> ORGANISM: artificial sequence
 33 <220> FEATURE:
 W--> 34 <221> NAME/KEY: VHconCDR3
 35 <222> LOCATION: (1)..(10)
 36 <223> OTHER INFORMATION: "Xaa" represents any amino acid residue
 38 <400> SEQUENCE: 1
 W--> 40 Xaa Xaa Xaa Xaa Arg Gly Xaa Phe Asp Xaa
 41 1 5 10
 44 <210> SEQ ID NO: 2
 45 <211> LENGTH: 8
 46 <212> TYPE: PRT
 47 <213> ORGANISM: artificial sequence
 49 <220> FEATURE:
 W--> 50 <221> NAME/KEY: VLconCDR3
 51 <222> LOCATION: (1)..(8)
 52 <223> OTHER INFORMATION: "Xaa" represents any amino acid residue
 55 <400> SEQUENCE: 2
 W--> 57 Gln Ser Tyr Asp Xaa Xaa Xaa Xaa
 58 1 5
 61 <210> SEQ ID NO: 3
 62 <211> LENGTH: 10
 63 <212> TYPE: PRT
 64 <213> ORGANISM: artificial sequence
 66 <220> FEATURE:
 W--> 67 <221> NAME/KEY: MS-GPC8-VH-CDR3, MS-GPC8-1-VH-CDR3, MS-GPC8-6-VH-CDR3, MS-GPC8-9-VH-
 W--> 68 CDR3, MS-GPC8-10-VH-CDR3, MS-GPC8-17-VH-CDR3, MS-GPC8-18-VH-CDR3, MS-GPC8-27-VH-

*Suggestion: Consult
Sequence Rules.*

see pp 1-6

**Does Not Comply
Corrected Diskette Needed**

*Please
explain
source of genetic material on*

*line (per Sequence
Rules)*

*see p.6 for
error explanation
(global
error)*

same error

same error as Sequence 1

same error

same

RAW SEQUENCE LISTING

DATE: 02/03/2004

PATENT APPLICATION: US/10/001,934B

TIME: 11:42:46

Input Set : N:\DA\pto.da.txt

Output Set: N:\CRF4\01292004\J001934B.raw

W--> 69 CDR3, MS-GPC8-6-2-VH-CDR3, MS-GPC8-6-13-VH-CDR3, MS-GPC8-6-19-VH-CDR3, MS-GPC8-
W--> 70 6-27-VH-CDR3, MS-GPC8-6-45-VH-CDR3, MS-GPC8-10-57-VH-CDR3, MS-GPC8-27-7-VH-CDR3,
W--> 71 MS-GPC8-27-10-VH-CDR3, MS-GPC8-27-41-VH-CDR3, MS-GPC8-6-47-VH-CDR3
72 <222> LOCATION: (1)..(10)
W--> 74 <223> OTHER INFORMATION:
W--> 74 <400> 3
76 Ser Pro Arg Tyr Arg Gly Ala Phe Asp Tyr
77 1 5 10
80 <210> SEQ ID NO: 4
81 <211> LENGTH: 8
82 <212> TYPE: PRT
83 <213> ORGANISM: artificial sequence
85 <220> FEATURE:
W--> 86 <221> NAME/KEY: MS-GPC8-10-VL-CDR3, MS-GPC8-10-57-VL-CDR3
87 <222> LOCATION: (1)..(8)
W--> 89 <223> OTHER INFORMATION:
W--> 89 <400> 4
90 Gln Ser Tyr Asp Leu Ile Arg His
91 1 5
94 <210> SEQ ID NO: 5
95 <211> LENGTH: 8
96 <212> TYPE: PRT
97 <213> ORGANISM: artificial sequence
99 <220> FEATURE:
W--> 100 <221> NAME/KEY: MS-GPC8-27-VL-CDR3, MS-GPC8-27-7-VL-CDR3, MS-GPC8-27-10-VL-CDR3, MS-
GPC8-27-
W--> 101 41-VL-CDR3
102 <222> LOCATION: (1)..(8)
W--> 104 <223> OTHER INFORMATION:
W--> 104 <400> 5
105 Gln Ser Tyr Asp Met Asn Val His
106 1 5
109 <210> SEQ ID NO: 6
110 <211> LENGTH: 13
111 <212> TYPE: PRT
112 <213> ORGANISM: artificial sequence
114 <220> FEATURE:
W--> 115 <221> NAME/KEY: VLconCDR1
116 <222> LOCATION: (1)..(13)
118 <220> FEATURE:
W--> 119 <221> NAME/KEY:
120 <222> LOCATION: (4)..(5)
121 <223> OTHER INFORMATION: "Xaa" represents any amino acid residue
123 <220> FEATURE:
W--> 124 <221> NAME/KEY:
125 <222> LOCATION: (9)..(9)
126 <223> OTHER INFORMATION: "Xaa" represents any amino acid residue
128 <220> FEATURE:
W--> 129 <221> NAME/KEY:
130 <222> LOCATION: (13)..(13)

RAW SEQUENCE LISTING

DATE: 02/03/2004

PATENT APPLICATION: US/10/001,934B

TIME: 11:42:46

Input Set : N:\DA\pto.da.txt

Output Set: N:\CRF4\01292004\J001934B.raw

131 <223> OTHER INFORMATION: "Xaa" represents any amino acid residue
 133 <400> SEQUENCE: 6
 W--> 134 Ser Gly Ser Xaa Xaa Asn Ile Gly Xaa Asn Tyr Val Xaa
 135 1 5 10
 138 <210> SEQ ID NO: 7
 139 <211> LENGTH: 13
 140 <212> TYPE: PRT *same*
 141 <213> ORGANISM: artificial sequence
 143 <220> FEATURE:
 W--> 144 <221> NAME/KEY: MS-GPC-8-10-57-VL-CDR1, MS-GPC-8-27-41-VL-CDR1 *same*
 145 <222> LOCATION: (1)..(13)
 W--> 147 <223> OTHER INFORMATION:
 W--> 147 <400> 7
 148 Ser Gly Ser Glu Ser Asn Ile Gly Asn Asn Tyr Val Gln
 149 1 5 10
 152 <210> SEQ ID NO: 8
 153 <211> LENGTH: 8
 154 <212> TYPE: PRT *same*
 155 <213> ORGANISM: artificial sequence
 157 <220> FEATURE:
 W--> 158 <221> NAME/KEY: Streptag *same*
 159 <222> LOCATION: (1)..(8)
 W--> 161 <223> OTHER INFORMATION:
 W--> 161 <400> 8
 163 Trp Ser His Pro Gln Phe Glu Lys
 164 1 5
 166 <210> SEQ ID NO: 9
 167 <211> LENGTH: 4
 168 <212> TYPE: PRT *same*
 169 <213> ORGANISM: artificial sequence
 171 <220> FEATURE:
 W--> 172 <221> NAME/KEY: FLAG *same*
 173 <222> LOCATION: (1)..(4)
 W--> 175 <223> OTHER INFORMATION:
 W--> 175 <400> 9
 177 Asp Tyr Lys Asp
 178 1
 181 <210> SEQ ID NO: 10
 182 <211> LENGTH: 17
 183 <212> TYPE: DNA *same*
 184 <213> ORGANISM: artificial sequence
 186 <220> FEATURE:
 W--> 187 <221> NAME/KEY: PrimerCRT5 *same*
 188 <222> LOCATION: (1)..(17)
 W--> 190 <223> OTHER INFORMATION:
 W--> 190 <400> 10
 191 gtggtggttc cgatatac
 194 <210> SEQ ID NO: 11
 195 <211> LENGTH: 44

17

RAW SEQUENCE LISTING

DATE: 02/03/2004

PATENT APPLICATION: US/10/001,934B

TIME: 11:42:46

Input Set : N:\DA\pto.da.txt

Output Set: N:\CRF4\01292004\J001934B.raw

196 <212> TYPE: DNA
 197 <213> ORGANISM: artificial sequence *same*
 199 <220> FEATURE:
 W--> 200 <221> NAME/KEY: PrimerCRT6 *same*
 201 <222> LOCATION: (1)..(44)
 W--> 203 <223> OTHER INFORMATION:
 W--> 203 <400> 11
 204 agcgtcacac tcggtgcggc ttctggctgg ccaagaacgg gtta 44
 207 <210> SEQ ID NO: 12
 208 <211> LENGTH: 13
 209 <212> TYPE: PRT
 210 <213> ORGANISM: artificial sequence *same*
 212 <220> FEATURE:
 W--> 213 <221> NAME/KEY: MS-GPC1-VL-CDR1,MS-GPC8-VL-CDR1,MS-GPC10-VL-CDR1,MS-GPC8-1-VL-
 CDR1,MS-
 W--> 214 GPC8-6-VL-CDR1,MS-GPC8-9-VL-CDR1,MS-GPC8-10-VL-CDR1, MS-GPC8-17-VL-CDR1,MS-
 GPC8-
 W--> 215 18-VL-CDR1,MS-GPC8-27-VL-CDR1,
 216 <222> LOCATION: (1)..(13)
 W--> 218 <223> OTHER INFORMATION:
 W--> 218 <400> 12
 219 Ser Gly Ser Ser Asn Ile Gly Ser Asn Tyr Val Ser
 220 1 5 10
 223 <210> SEQ ID NO: 13
 224 <211> LENGTH: 13
 225 <212> TYPE: PRT
 226 <213> ORGANISM: artificial sequence *same*
 228 <220> FEATURE:
 W--> 229 <221> NAME/KEY: MS-GPC8-6-2-VL-CDR1
 230 <222> LOCATION: (1)..(13)
 W--> 232 <223> OTHER INFORMATION:
 W--> 232 <400> 13
 233 Ser Gly Ser Glu Ser Asn Ile Gly Ser Asn Tyr Val His
 234 1 5 10
 237 <210> SEQ ID NO: 14
 238 <211> LENGTH: 13
 239 <212> TYPE: PRT
 240 <213> ORGANISM: artificial sequence *same*
 242 <220> FEATURE:
 W--> 243 <221> NAME/KEY: MS-GPC8-6-19-VL-CDR1
 244 <222> LOCATION: (1)..(13)
 W--> 246 <223> OTHER INFORMATION:
 W--> 246 <400> 14
 247 Ser Gly Ser Glu Ser Asn Ile Gly Ser Asn Tyr Val Ala
 248 1 5 10
 251 <210> SEQ ID NO: 15
 252 <211> LENGTH: 13
 253 <212> TYPE: PRT
 254 <213> ORGANISM: artificial sequence *same*
 256 <220> FEATURE:
 W--> 257 <221> NAME/KEY: MS-GPC8-6-27-VL-CDR1

RAW SEQUENCE LISTING

DATE: 02/03/2004

PATENT APPLICATION: US/10/001,934B

TIME: 11:42:46

Input Set : N:\DA\pto.da.txt

Output Set: N:\CRF4\01292004\J001934B.raw

258 <222> LOCATION: (1)..(13)
W--> 260 <223> OTHER INFORMATION:
W--> 260 <400> 15
261 Ser Gly Ser Asp Ser Asn Ile Gly Ala Asn Tyr Val Thr
262 1 5 10
265 <210> SEQ ID NO: 16
266 <211> LENGTH: 13
267 <212> TYPE: PRT
268 <213> ORGANISM: artificial sequence
270 <220> FEATURE: same
W--> 271 <221> NAME/KEY: MS-GPC8-6-45-VL-CDR1
272 <222> LOCATION: (1)..(13)
W--> 274 <223> OTHER INFORMATION:
W--> 274 <400> 16
275 Ser Gly Ser Glu Pro Asn Ile Gly Ser Asn Tyr Val Phe
276 1 5 10
279 <210> SEQ ID NO: 17
280 <211> LENGTH: 13
281 <212> TYPE: PRT
282 <213> ORGANISM: artificial sequence
284 <220> FEATURE: same
W--> 285 <221> NAME/KEY: MS-GPC8-27-7-VL-CDR1
286 <222> LOCATION: (1)..(13)
W--> 288 <223> OTHER INFORMATION:
W--> 288 <400> 17
289 Ser Gly Ser Glu Ser Asn Ile Gly Asn Asn Tyr Val Gly
290 1 5 10
293 <210> SEQ ID NO: 18
294 <211> LENGTH: 13
295 <212> TYPE: PRT
296 <213> ORGANISM: artificial sequence
298 <220> FEATURE: same
W--> 299 <221> NAME/KEY: MS-GPC8-27-10-VL-CDR1
300 <222> LOCATION: (1)..(13)
W--> 302 <223> OTHER INFORMATION:
W--> 302 <400> 18
303 Ser Gly Ser Glu Ser Asn Ile Gly Ala Asn Tyr Val Asn
304 1 5 10
307 <210> SEQ ID NO: 19
308 <211> LENGTH: 10
309 <212> TYPE: PRT
310 <213> ORGANISM: artificial sequence
312 <220> FEATURE: same
W--> 313 <221> NAME/KEY: MS-GPC1-VH-CDR3
314 <222> LOCATION: (1)..(10)
W--> 316 <223> OTHER INFORMATION:
W--> 316 <400> 19
318 Gln Tyr Gly His Arg Gly Gly Phe Asp His
319 1 5 10

RAW SEQUENCE LISTING ERROR SUMMARY
 PATENT APPLICATION: US/10/001,934B

DATE: 02/03/2004
 TIME: 11:42:47

Input Set : N:\DA\pto.da.txt
 Output Set: N:\CRF4\01292004\J001934B.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 1,2,3,4,7,10
 Seq#:2; Xaa Pos. 5,6,7,8
 Seq#:6; Xaa Pos. 4,5,9,13

Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:3; Line(s) 70
 Seq#:5; Line(s) 100
 Seq#:12; Line(s) 214
 Seq#:41; Line(s) 1333,1334
 Seq#:60; Line(s) 1938

Use of <220> Feature (NEW RULES):

error explanation

Sequence(s) are missing the <220> Feature and associated headings.

Use of <220> to <223> is MANDATORY if <213> ORGANISM is "Artificial Sequence" or "Unknown". Please explain source of genetic material in <220> to <223> section (See "Federal Register," 6/01/98, Vol. 63, No. 104, pp.29631-32) (Sec.1.823 of new Rules)

Seq#:3,4,5,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29
 Seq#:30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53
 Seq#:54,55,56,57,58,59,60,61,62,1,2,6

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/001,934B

DATE: 02/03/2004

TIME: 11:42:47

Input Set : N:\DA\pto.da.txt

Output Set: N:\CRF4\01292004\J001934B.raw

L:34 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1
 L:40 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0
 L:50 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:2
 L:57 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:0
 L:67 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:3
 L:68 M:257 W: Feature value mis-spelled or invalid, Describe feature in <223> for SEQ ID#:3
 L:69 M:257 W: Feature value mis-spelled or invalid, Describe feature in <223> for SEQ ID#:3
 L:70 M:257 W: Feature value mis-spelled or invalid, Describe feature in <223> for SEQ ID#:3
 L:71 M:257 W: Feature value mis-spelled or invalid, Describe feature in <223> for SEQ ID#:3
 L:74 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:3, <213>
 ORGANISM:artificial sequence
 L:74 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:3,Line#:74
 L:86 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4
 L:89 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:4, <213>
 ORGANISM:artificial sequence
 L:89 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:4,Line#:89
 L:100 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5
 L:101 M:257 W: Feature value mis-spelled or invalid, Describe feature in <223> for SEQ ID#:5
 L:104 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:5, <213>
 ORGANISM:artificial sequence
 L:104 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:5,Line#:104
 L:115 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:6
 L:119 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:6
 L:124 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:6
 L:129 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:6
 L:134 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0
 L:144 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:7
 L:147 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:7, <213>
 ORGANISM:artificial sequence
 L:147 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:7,Line#:147
 L:158 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:8
 L:161 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:8, <213>
 ORGANISM:artificial sequence
 L:161 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:8,Line#:161
 L:172 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:9
 L:175 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:9, <213>
 ORGANISM:artificial sequence
 L:175 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:9,Line#:175
 L:187 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:10
 L:190 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:10, <213>
 ORGANISM:artificial sequence
 L:190 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:10,Line#:190
 L:200 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:11
 L:203 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:11, <213>
 ORGANISM:artificial sequence
 L:203 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:11,Line#:203
 L:213 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:12
 L:214 M:257 W: Feature value mis-spelled or invalid, Describe feature in <223> for SEQ ID#:12
 L:215 M:257 W: Feature value mis-spelled or invalid, Describe feature in <223> for SEQ ID#:12
 L:218 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:12, <213>
 ORGANISM:artificial sequence
 L:218 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:12,Line#:218
 L:229 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:13

L:232 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:13, <213>
ORGANISM:artificial sequence
L:232 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:13,Line#:232
L:243 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:14
L:246 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:14, <213>
ORGANISM:artificial sequence

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/001,934B

DATE: 02/03/2004

TIME: 11:42:47

Input Set : N:\DA\pto.da.txt

Output Set: N:\CRF4\01292004\J001934B.raw

L:246 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:14,Line#:246
L:257 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:15
L:260 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:15, <213>
ORGANISM:artificial sequence
L:260 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:15,Line#:260
L:271 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:16
L:274 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:16, <213>
ORGANISM:artificial sequence
L:274 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:16,Line#:274
L:285 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:17
L:288 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:17, <213>
ORGANISM:artificial sequence
L:288 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:17,Line#:288
L:299 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:18
L:302 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:18, <213>
ORGANISM:artificial sequence
L:302 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:18,Line#:302
L:313 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:19
L:316 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:19, <213>
ORGANISM:artificial sequence
L:316 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:19,Line#:316
L:328 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:20
L:331 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:20, <213>
ORGANISM:artificial sequence
L:331 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:20,Line#:331
L:343 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:21
L:346 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:21, <213>
ORGANISM:artificial sequence
L:346 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:21,Line#:346
L:358 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:22
L:361 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:22, <213>
ORGANISM:artificial sequence
L:361 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:22,Line#:361
L:373 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:23
L:376 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:23, <213>
ORGANISM:artificial sequence
L:376 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:23,Line#:376
L:388 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:24
L:391 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:24, <213>
ORGANISM:artificial sequence
L:391 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:24,Line#:391
L:403 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:25
L:406 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:25, <213>
ORGANISM:artificial sequence
L:406 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:25,Line#:406
L:417 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:26
L:420 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:26, <213>
ORGANISM:artificial sequence
L:420 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:26,Line#:420
L:432 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:27
L:435 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:27, <213>
ORGANISM:artificial sequence
L:435 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:27,Line#:435

L:446 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:28
 L:449 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:28, <213>
 ORGANISM:artificial sequence
 L:449 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:28,Line#:449
 L:479 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:29
 L:494 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:30
 L:508 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:31
 L:540 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:32
 L:573 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:33
 L:704 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:34

VERIFICATION SUMMARY

PATENT APPLICATION: **US/10/001,934B**

DATE: 02/03/2004

TIME: 11:42:47

Input Set : N:\DA\pto.da.txt

Output Set: N:\CRF4\01292004\J001934B.raw

L:864 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:35
L:1043 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:36
L:1194 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:37
L:1230 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:38
L:1263 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:39
L:1299 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:40